Idexx Laboratories — Q2 2025 Earnings Presentation

4 slides from Idexx Laboratories's earnings presentation, Aug 4, 2025

Slide 1: IDEXX Q2 2025 Earnings Highlights
IDEXX Q2 2025 2024 Earnings Highlights (NASDAQ: (NASDAQ: IDXX) IDXX) Operating Diluted Revenue Profit Earnings Per Share $1,109M $373M $3.63 Reported growth: +11% 34% of Revenue Reported growth: +49% Organic growth: +9% YoY change in basis points: CAG Diagnostics Recurring Reported +730 bps Comparab
Slide 2: 2025 Growth and Financial Performance Outlook
IDEXX Q2 2025 Earnings Highlights (NASDAQ: IDXX) 2025 Growth and Financial Performance Outlook Commentary • Increases full year guidance to reflect solid CAG Diagnostics recurring revenue performance, outlook for higher IDEXX inVue Dx instrument placements, and associated revenues, and benefit of fo
Slide 3: U.S. Companion Animal Practice Growth Update
U.S. Companion Animal Practice Growth Update As of June 30, 2025 Total Practice Revenue and Visit Growth Weighted Average Year-over-Year % Change Per Practice* — 18.0% 15% 10% Practice Revenue 5% 3.4% 2.0% 2.1% 4 60g 0% Total Visits -2.1% = 5% 45% -3.4% 72.7% 3.2% 3.6% Qi_ Q2 Q3 24 Qi Q2 Q3 24 ai a2
Slide 4: Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice
U.S. Companion Animal Practice Growth Update As of June 30, 2025 Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice** + 6.5% + 4.5% Q2’2025 Year-Over-Year Growth (%) - 2.5% + 0.5% Q2’2024 - 1.5% - 0.5% i ___ + 7.0% + 10.0% Q2 Average 2020-2023 + 1.0% + 2.0% I Clinical Visit